These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37745410)

  • 1. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
    Phan T; Zitzmann C; Chew KW; Smith DM; Daar ES; Wohl DA; Eron JJ; Currier JS; Hughes MD; Choudhary MC; Deo R; Li JZ; Ribeiro RM; Ke R; Perelson AS;
    bioRxiv; 2023 Sep; ():. PubMed ID: 37745410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
    Phan T; Zitzmann C; Chew KW; Smith DM; Daar ES; Wohl DA; Eron JJ; Currier JS; Hughes MD; Choudhary MC; Deo R; Li JZ; Ribeiro RM; Ke R; Perelson AS;
    PLoS Pathog; 2024 Apr; 20(4):e1011680. PubMed ID: 38635853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
    Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
    Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.
    Choudhary MC; Chew KW; Deo R; Flynn JP; Regan J; Crain CR; Moser C; Hughes MD; Ritz J; Ribeiro RM; Ke R; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Fletcher CV; Daar ES; Wohl DA; Eron JJ; Currier JS; Parikh UM; Sieg SF; Perelson AS; Coombs RW; Smith DM; Li JZ;
    Nat Microbiol; 2022 Nov; 7(11):1906-1917. PubMed ID: 36289399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
    Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC
    Trials; 2021 May; 22(1):363. PubMed ID: 34034784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy.
    Choudhary MC; Chew KW; Deo R; Flynn JP; Regan J; Crain CR; Moser C; Hughes M; Ritz J; Ribeiro RM; Ke R; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Fletcher CV; Daar ES; Wohl DA; Eron JJ; Currier JS; Parikh UM; Sieg SF; Perelson AS; Coombs RW; Smith DM; Li JZ;
    medRxiv; 2021 Sep; ():. PubMed ID: 34545376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2.
    Choudhary MC; Deo R; Evering TH; Chew KW; Giganti MJ; Moser C; Ritz J; Regan J; Flynn JP; Crain CR; Wohl DA; Currier JS; Eron JJ; Margolis D; Zhu Q; Zhon L; Ya L; Greninger AL; Hughes MD; Smith D; Daar ES; Li JZ
    J Infect Dis; 2024 Aug; 230(2):394-402. PubMed ID: 38716969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.
    Boucau J; Chew KW; Choudhary M; Deo R; Regan J; Flynn JP; Crain CR; Hughes MD; Ritz J; Moser C; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Coombs RW; Fischer WA; Daar ES; Wohl DA; Eron JJ; Currier JS; Smith DM; Li JZ; Barczak AK;
    medRxiv; 2021 Dec; ():. PubMed ID: 35018382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.
    Boucau J; Chew KW; Choudhary MC; Deo R; Regan J; Flynn JP; Crain CR; Hughes MD; Ritz J; Moser C; Dragavon JA; Javan AC; Nirula A; Klekotka P; Greninger AL; Coombs RW; Fischer WA; Daar ES; Wohl DA; Eron JJ; Currier JS; Smith DM; ; Li JZ; Barczak AK;
    Cell Rep Med; 2022 Jul; 3(7):100678. PubMed ID: 35793677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
    Ferré VM; Peiffer-Smadja N; Kramer L; Coppée R; Kante A; Debarge M; Choquet C; Saint Joannis T; Bouzid D; Messika J; Le Grand J; Thy M; Kernéis S; Descamps D; Visseaux B; Ghosn J
    Microbiol Spectr; 2022 Oct; 10(5):e0215222. PubMed ID: 36125289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
    Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
    Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis.
    Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW
    Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.